

Company Secretary & CFO Resignation and Appointment

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) ("**NeuroScientific**" or "**the Company**") advises the appointment of Chris Achurch as Company Secretary, following the resignation of Abby Macnish Niven, as CFO and Company Secretary, effective today 6 February 2024.

Chris has worked in the finance industry for over 15 years and provides consulting services to a number of ASX listed and unlisted Companies.

NSB's Chairman, Chris Ntoumenopoulos, said, "We welcome Chris and thank Abby for her time at the Company. Abby has been an integral part of NeuroScientific for the past four years, and we wish her every success in the future."

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Chris Ntoumenopoulos
Chairman
ir@neuroscientific.com
+ 61 8 6382 1805

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.